TrialPath
Recruiting

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT07612267 · Eli Lilly and Company
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
About this study
The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication. Participation in this study could last up to 94 days, including screening and follow-up period.
Eligibility criteria
Inclusion Criteria: Study Participants: * Mothers who are at minimum 18 years of age and their infants who are at least 36 weeks gestation age at birth and at least 3 weeks old by Study Day 0 * Multiple births may be allowed following discussion with the medical monitor. Note: in the opinion of the healthcare practitioner (HCP), there are no infant or maternal issues that would preclude the mother participant or the infant from participation * Lactation history is well established, with the mother exclusively breastfeeding her infant * Mother participant is receiving mirikizumab therapeutically for an approved diagnosis (having received at least 2 doses of mirikizumab SC maintenance therapy every 4 weeks prior to study Day 0) * Have a breastfed infant who can feed from a bottle with previously stored breast milk or formula Exclusion Criteria: * Have a history of inadequate lactation, for multiparous participants who have previously breastfed * Have a significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking mirikizumab, or of interfering with the interpretation of data * Have any condition that fulfills any contraindication stated in the label. All warnings and precautions stated in the label need to be considered * Have a history of breast augmentation procedures judged to have a clinical impact on breast milk expression such as breast reduction surgery and some breast implants, or current evidence of acute or chronic conditions affecting breasts and potentially interfering with breast milk collection * Have received any live vaccine (that is, live attenuated) within less than 4 weeks or inactivated vaccine within less than 2 weeks before enrollment or intend to receive a live vaccine during the study or an inactivated vaccine 2 weeks postdose, the mother participant must be given the vaccine at an injection site remote from mirikizumab administration
Study design
Enrollment target: 14 participants
Allocation: na
Masking: none
Age groups: child, adult, older_adult
Timeline
Starts: 2026-08-05
Estimated completion: 2028-09
Last updated: 2026-11-04
Interventions
Drug: Mirikizumab
Primary outcomes
  • • Concentration of Mirikizumab in Breast Milk (Predose up to 28 Days)
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactTrial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · contact · LillyTrials@Lilly.com · 1-317-615-4559
ContactPhysicians interested in becoming principal investigators please contact · contact · clinical_inquiry_hub@lilly.com
InvestigatorCall 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · study_director, Eli Lilly and Company
All locations (20)
Northwest GastroenterologistNot Yet Recruiting
Glenview, Illinois, United States
University of IowaNot Yet Recruiting
Iowa City, Iowa, United States
Johns Hopkins Bayview Medical CenterNot Yet Recruiting
Baltimore, Maryland, United States
Digestive Disease Medicine of Central New YorkNot Yet Recruiting
Utica, New York, United States
University Hospitals Cleveland Medical CenterNot Yet Recruiting
Cleveland, Ohio, United States
GI ResearchNot Yet Recruiting
Columbia, Canada
Aarhus Universitetshospital, Aarhus SygehusNot Yet Recruiting
Aarhus N, Denmark
Slagelse HospitalNot Yet Recruiting
Slagelse, Denmark
Interdisziplinäres Crohn Colitis Centrum Rhein-MainNot Yet Recruiting
Frankfurt am Main, Germany
Klinikum Ernst von BergmannNot Yet Recruiting
Potsdam, Germany
Rabin Medical Center - PPDSNot Yet Recruiting
HaMerkaz, Israel
Shaare Zedek Medical CenterRecruiting
Jerusalem, Israel
Chaim Sheba Medical CenterNot Yet Recruiting
Ramat Gan, Israel
Tel Aviv Sourasky Medical Center Ichilov - PPDSRecruiting
Tel Aviv, Israel
Fondazione Policlinico Universitario A Gemelli - Rome - PPDSNot Yet Recruiting
Lazio, Italy
Ospedale San Raffaele S.r.l. - PPDSNot Yet Recruiting
Lombardia, Italy
Ospedale di Rho - UOC GastroenterologiaNot Yet Recruiting
Rho, Italy
Ospedale Sandro PertiniNot Yet Recruiting
Roma, Italy
DC-MED Micha Kowalski S.K. - ul. Kilinskiego 6Not Yet Recruiting
Radom, Poland
WIP Warsaw IBD Point Profesor KierkusNot Yet Recruiting
Warsaw, Poland
A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication · TrialPath